BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20240101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250506
DTEND;VALUE=DATE:20250509
DTSTAMP:20260515T094303
CREATED:20250116T114600Z
LAST-MODIFIED:20250116T114600Z
UID:40301-1746489600-1746748799@www.pharmajournalist.com
SUMMARY:3rd mRNA Process Development & Manufacturing Summit Europe
DESCRIPTION:The 3rd mRNA Process Development & Manufacturing Summit 2025 returns as Europe’s premier industry-focused forum\, dedicated to optimizing process development for mRNA therapeutics and vaccines. This event will address end-to-end process optimisation\, regulatory compliance to streamline approvals\, while also advancing scalable and cost-efficient manufacturing solutions\, to support drug developers in delivering safer and more effective mRNA drugs to patients faster. \nBringing together leading experts from CEPI\, Merck\, CureVac\, BioNTech\, Altamira\, Genevation\, and more\, this summit will showcase cutting-edge advancements in end-to-end process development and manufacturing to support the production of high-quality\, cost-effective mRNA therapeutics at scale. \nDownload the event guide for full details: https://ter.li/4omn9n
URL:http://www.pharmajournalist.com/event/3rd-mrna-process-development-manufacturing-summit-europe/
LOCATION:Hotel Palace Berlin\, Germany
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250506
DTEND;VALUE=DATE:20250509
DTSTAMP:20260515T094303
CREATED:20250220T124530Z
LAST-MODIFIED:20250220T124530Z
UID:40548-1746489600-1746748799@www.pharmajournalist.com
SUMMARY:2nd ADC Payload Summit
DESCRIPTION:The 2nd ADC Payload Summit (May 6-8 | Boston\, MA) is the first and only conference exclusively focusing on ADC payloads\, helping you to reimagine the medicinal chemistry of traditional cytotoxic payloads while scouting the next generation of ADC payload innovations. \n \nWith novel payload categories such as degraders\, RNA polymerase II inhibitors\, immunomodulators\, gene silences\, and splice modulators entering the clinic\, don’t miss this opportunity to meet with fellow peers to explore the benefits of these diverse mechanisms of action to develop the next blockbuster ADC. \nThis event will also feature cutting-edge data presentations from emerging players in the field\, including Lycia Therapeutics and Heidelberg Pharma\, showcasing their latest advancements in payload technologies and clinical trial outcomes. With 80+ professionals from across the ADC landscape in attendance\, the summit offers ample networking opportunities to foster collaboration\, exchange ideas\, and drive the future of ADC therapy forward. \nOver three days of deep discussions and collaborative sessions\, attendees will gain practical insights into optimizing payload efficacy\, improving structure-activity relationships\, and exploring the latest payload classes entering the clinic. \nHere are some of the agenda highlights you cannot afford to miss: \n– Gain insights from Eisai on “Engineering STING/TLR Agonist Payloads to Amplify Anti-Tumor Immune Responses Without Triggering Cytokine Induction” exploring the therapeutic niche and potential of STING agonist payloads. \n– Join Takeda in “Navigating the Evolution of ADC Payloads – From Topo1 Success to Future Innovation” to discuss why Topo1 inhibitors dominated the clinic so fast\, what other modes of action and payload classes need to do to match that clinical success\, and where there is whitespace for novel payloads to gain ground in a competitive ADC landscape. \n– Hear from Merck on “Accelerating Degrader-Antibody Conjugate Design Through Strategic Integration of Traditional ADC & Expertise in TPD” to learn about translating physicochemical property optimization strategies from traditional ADCs to address unique degrader payload solubility and stability challenges. \nDon’t miss this opportunity to connect with the ADC community and shape the future of payload design. Join us in Boston for this exclusive event and be at the forefront of ADC innovation. \nTo know more visit: https://ter.li/j0dvm6
URL:http://www.pharmajournalist.com/event/2nd-adc-payload-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR